Marco's Morning Report — Wednesday, September 2, 2026

Morning, Marco. Munich is over and the journals took the handoff — yesterday's Annals and JAMA both dropped something that touches how you admit. One tells you exactly how much weight the GLP-1 class actually takes off people without diabetes; the other tells you a stroke procedure keeps failing the test. Underneath: the cyclospora number is much bigger than the outbreak number, Edouard came ashore on the Texas-Louisiana line, and the debate is the one your colleagues are about to argue in the break room during open enrollment.

A · Top Stories

Evidence · Obesity

Annals puts a number on every GLP-1 in people without diabetes — and the spread between agents is enormous

Published yesterday in Annals of Internal Medicine: a systematic review of GLP-1 receptor agonists and dual/triple co-agonists for obesity in adults without diabetes. Head-to-head on mean weight loss: retatrutide 12 mg weekly, 22.1% at 48 weeks; tirzepatide 15 mg weekly, 17.8% at 72 weeks; semaglutide 2.4 mg weekly, 13.9% at 68 weeks; liraglutide 3.0 mg daily, 5.8% at 26 weeks. BMI, waist circumference and blood pressure fell across all agents. Adverse events were overwhelmingly gastrointestinal, transient, and mild-to-moderate; serious events were rare. Full review · patient summary.

Why it matters to you: You are admitting these patients now — the Medicare Bridge enrollees, the cash-pay compounded-semaglutide crowd, and the ones who stopped three weeks ago and don't remember why. Two things to carry off this paper. First, the fourfold gap between liraglutide and retatrutide means "on a GLP-1" is not a medication history; the agent and the dose are the history. Second, the safety profile being GI-dominant is exactly why the drug matters to you at 2 a.m. — the elderly admit with a week of nausea, poor intake, and a creatinine of 1.9 is the phenotype, and the review's reassurance about "mild-to-moderate, transient" was earned in trial populations who were younger and better monitored than the person in your bed.

Suggested action: If your med-rec template still captures GLP-1s as a drug name only, this is the paper to hand the pharmacy lead when you ask for agent, dose, and last-dose date as three separate fields. You've been circling this for two weeks; the numbers above are the argument.

Trial · Stroke

DISCOUNT: thrombectomy for medium and distal vessel occlusions missed again — and bled more

In the September 1 issue of JAMA (336:9, 755–764). The trial randomized adults with acute ischemic stroke from a primary, isolated medium or distal vessel occlusion to mechanical thrombectomy plus medical therapy vs. medical therapy alone. No significant difference in good clinical outcome at 90 days, and a higher rate of hemorrhagic complications in the thrombectomy arm. The trial was stopped early for safety and futility. Abstract. That makes three: DISCOUNT joins ESCAPE-MeVO (symptomatic ICH 5.4% vs. 2.2%, mortality 13.3% vs. 8.4%) and DISTAL, all negative in broadly selected populations.

Why it matters to you: This is a night-shift conversation, not a neurology conference conversation. The 3 a.m. call where a patient with a modest NIHSS has an M3 or A2 occlusion on CTA and someone asks whether to activate transfer — three randomized trials now say that in an unselected patient, the procedure doesn't improve the 90-day outcome and does increase bleeding. The default has flipped. "We can reach it" is no longer an indication, and the burden of justification sits with the person proposing the catheter.

Talking point: Worth raising the next time your group meets with neurology or the stroke coordinator — not to block anything, but to find out what your center's selection criteria for distal thrombectomy actually are, and whether they've moved since January.

Update · Public health

Update: the national cyclospora number is roughly triple the outbreak number

We've been tracking the iceberg-lettuce outbreak — 11,458 confirmed illnesses across 20 states traced to Taylor Farms de México product. The wider CDC picture is a different scale: close to 29,000 confirmed and probable cyclosporiasis cases across 48 states and DC since May 1, more than 900 hospitalizations, and 2 deaths. For context, the same May–August window last year produced 1,180 cases nationally. This is the worst reported cyclosporiasis year on record in the United States. The one piece of good news: CDC's daily case curve is now trending down. CDC case data · investigation update.

Why it matters to you: The gap between 11,458 and 29,000 is the gap between what's been traced to a single supplier and what's actually circulating — meaning a produce-exposure history that comes back negative for shredded iceberg does not lower your pretest probability much. In an elderly admit with two to three weeks of watery diarrhea, anorexia, profound fatigue and weight loss, cyclospora belongs on the list, and it will not show up on a routine ova-and-parasite unless someone specifically asks for it. It also does not respond to the antibiotics you would reach for empirically — TMP-SMX is the treatment.

Suggested action: Confirm whether your GI multiplex panel includes Cyclospora cayetanensis and what the turnaround is. If it doesn't, know before your next prolonged-diarrhea admit that you have to order the modified acid-fast stain by name.

B · The Debate

Should employers keep paying for GLP-1s for weight loss?

Why it's live right now: Business Group on Health released its 2026 GLP-1 survey yesterday: 67% of large employers currently cover the drugs for weight management, but of those, only 72% say they are likely to continue in 2027 and 10% say they likely will not — against projected double-digit pharmacy cost increases. STAT ran "GLP-1s are breaking employers" on Monday. The Annals review above landed the same week, which is the whole tension: the efficacy evidence keeps strengthening while the coverage keeps narrowing.

The case for keeping coverage

Yoni Freedhoff, MD — obesity medicine, University of Ottawa, via Medscape

Obesity is a chronic disease with a remissible course, and these are its first-line pharmacologic treatment — by Freedhoff's framing, among the most important new medication classes of our lifetimes. No plan asks whether a statin or an antihypertensive "pays for itself" inside a two-year budget window; they are covered because the underlying condition is a disease and the drug treats it. Singling out obesity drugs for a return-on-investment test that no other class has to pass is a judgment about obesity, not about economics. He points at the coverage map as evidence of how arbitrary it is: only 19% of firms with 200+ workers cover GLP-1s for weight loss in their largest plan, rising to 43% at 5,000+ employees — meaning access turns on employer size rather than clinical need. The Annals numbers, he'd argue, are the strongest response available: 14% to 22% sustained weight loss with mostly transient GI side effects is not a lifestyle benefit.

The case for cutting back

Ellen Kelsay — President & CEO, Business Group on Health

Nearly eight in ten employers now report GLP-1s driving their health care costs up, and Kelsay's position is that companies "cannot ignore the reality that GLP-1s have significant implications for health care budgets — and overall affordability." The affordability point is the sharp end of it: every dollar of GLP-1 spend in a self-funded plan comes out of the same pool that sets premiums and deductibles for everyone in the plan, including workers who will never take the drug. Employers who have covered the class for two or three years report they have mostly not yet seen the promised downstream savings in their own claims data — no measurable drop in obesity rates or bariatric surgery — and an NBER working paper asking whether GLP-1s pay for themselves concluded they do not, for the employer. With 87% expecting an oral formulation to push demand higher still, the argument is that a benefit which grows without bound isn't a benefit design, it's an unfunded liability.

Where it might land: 2027 plan-year designs are being finalized this month and next, so the answer at most large employers will be set before Thanksgiving — likely as tightened utilization management (biometric eligibility, mandatory weight-management program enrollment, restricted prescribers) rather than a clean yes or no.

C · On My Radar

Hormuz — tankers hit two nights running. Two supertankers were struck by unidentified projectiles inside the US-guarded southern corridor on the evening of 31 August, and UKMTO reported a third tanker struck the following day. President Pezeshkian says Iran will reciprocate immediately — including free navigation through the strait — if Washington returns to the June memorandum. Al Jazeera has a useful explainer on whether Iran can actually mine the strait with rockets as the US claims.

Edouard came ashore, and it wasn't Florida's problem. Tropical Storm Edouard made landfall at 2:20 p.m. CDT yesterday near Johnson Bayou, Louisiana at 60 mph — the season's third landfalling storm — with 5 to 9 inches of rain and tornado risk pushing inland across southeast Texas. Track and impacts. September 10 is still the climatological peak; the ride-out roster question from yesterday stands.

Amendment 3 would cost Florida's public hospitals an estimated $323M over three years. New Florida Policy Institute analysis: 28 hospital and health-care taxing districts levy property taxes to fund indigent care, and the homestead-exemption increase on the November 3 ballot would hit them hard — North Broward Hospital District over $100M, Palm Beach County's Health Care District $66.4M, Jackson Health $63.9M. Needs 60% to pass. WUSF · FPI report.

COVID: the two surveillance systems still disagree. CDC rates national activity low; Stanford's WastewaterSCAN has August concentrations up roughly 106% over July and calls it high. Texas leads the country in wastewater levels. XFG.1.1 ("Stratus") has overtaken NB.1.8.1 ("Nimbus") at an estimated 22–40% of US cases. Summary. The South and West are rising fastest — worth knowing when you're deciding whether to test the vague elderly admit.

Mets 2, Rays 6. At Tropicana Field last night: Lindor homered to right in the first, Manaea took the loss, Freddy Peralta got the win for Tampa Bay. The better news is roster news — Juan Soto was activated off the IL on Monday and Mark Vientos is back as well, so the lineup you've been waiting on since June is finally intact for the September run. Box score.

Puerto Rico: 72% of the island is in drought and the rationing hasn't lifted. More than 180,000 customers are cycling through 48 hours without running water at a time, San Juan is into a fourth week of mandatory schedules, and July was the driest month for the capital in more than 120 years. Forecasters expect dry conditions at least through September. CNN · NASA Earth Observatory imagery.

Cuba: schools opened on time; tourism did not recover. Classrooms reopened yesterday for roughly 1.4 million students, with AP reporting families using borrowed horses where school buses aren't running and shortages of fuel, teachers and uniforms. Separately, the national statistics office reported 419,000 visitors January through July against 1.1 million in the same period last year — a 62% collapse. AP via Washington Times.

D · Trends to Watch

The evidence for obesity drugs and the financing for obesity drugs are moving in opposite directions. Within seven days: an Annals review confirming 14–22% weight loss with a benign side-effect profile, a Business Group survey showing coverage retreating for 2027, and employers reporting they haven't seen the savings in their own claims. That divergence doesn't resolve — it gets resolved for patients, by benefit design, and you'll meet the result as abrupt discontinuations on your admission lists this winter.

"Reachable" has stopped meaning "treatable" in acute stroke. DISTAL, ESCAPE-MeVO and now DISCOUNT have all failed in medium and distal occlusions, two of the three with a hemorrhage signal. Catheter technology outran the evidence for reaching smaller vessels, and the field is now walking back to selection criteria. Expect the next phase to be about defining which distal occlusions are worth treating rather than whether they can be.

Outbreak headlines are increasingly a subset of the outbreak. The traced cyclospora count is 11,458; the national count is near 29,000. Attribution requires a supplier, a lot number and a traceback; transmission doesn't. The number that gets a press release is the number someone could pin on a product, which is systematically smaller than the number of people who are sick — a useful correction to apply to every outbreak figure you read this year.

E · Ideas & Opportunities

Ask what your own plan is doing with GLP-1 weight-management coverage for 2027. Open enrollment is coming and the Business Group numbers say roughly one in ten covering employers is dropping it. Your colleagues will ask you, as the doctor in the room, whether the drugs are worth it — better to know your own hospital's answer before the email goes out than after.

Find out who owns the distal-occlusion call overnight at your center. Ten-minute question for the stroke coordinator: after DISCOUNT, what are the selection criteria for MeVO thrombectomy, and who makes the call when you're the admitting physician at 3 a.m. and neurointervention is at home? Better asked on a Tuesday than during a transfer.

Post-nights watch: I Want Your Sex started streaming yesterday at 91% on Rotten Tomatoes, and Coyote vs. Acme is still in theaters at 96% with an A CinemaScore. The Acme one is the better coffee-and-daylight option.